More: NASA announces Voyager 1 resumes science data transmission...
More: NASA announces Voyager 1 resumes science data transmission...
In the medical field, a breakthrough achievement by Chinese scientists has drawn widespread attention. Led by Professor Sun Beicheng of the First Affiliated Hospital of Anhui Medical University and working in collaboration with Professor Wei Hongjiang's team from Yunnan Agricultural University, they have successfully performed the world's first heterologous organ transplantation surgery on a living person using a pig's liver. The 71-year-old liver cancer patient has seen multiple indicators such as liver function return to normal after receiving the transgenic pig liver transplant, and the patient is even able to get out of bed and move around on their own. The success of this surgery not only marks a significant advance in xenotransplantation technology but also lays the foundation for the clinical application of related treatment methods.
Significant advancement in the field of space exploration is equally eye-catching. The United States National Aeronautics and Space Administration (NASA) has reallocated and repaired issues faced by the Voyager 1 probe. After careful investigation and technical intervention, NASA engineers successfully restored the probe's capacity to transmit scientific data. During this repair process, there were still four scientific instruments operating on Voyager 1, including the plasma wave system and magnetometer. This successful repair provides hope for the extended operational life of the probe and enhances our understanding of space exploration.
In the area of drug regulation, the National Medical Products Administration has recently approved Eli Lilly's Mounjaro® (also known as tirzepatide injection) for the market. This medication is used to treat type 2 diabetes (T2DM) in adult patients. It previously gained market anticipation for its unexpected weight loss effect seen in clinical trials, but the current approval does not include the indication for obesity treatment.
Tirzepatide was initially approved by the U.S. Food and Drug Administration (FDA) in 2022 to treat type 2 diabetes. After demonstrating impressive weight reduction results in clinical trials, it received FDA approval in November 2023 to extend its use for weight loss treatment. However, in China, tirzepatide is currently only approved for controlling blood sugar in adult patients with type 2 diabetes, not including weight loss treatment. Pharmaceutical company Eli Lilly has indicated that the indication for long-term weight management with tirzepatide is still under review. Tirzepatide is the first and currently the only therapeutic agent globally that can selectively bind to and activate two types of incretin receptors—glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor, a GIP/GLP-1 receptor agonist. This treatment not only effectively lowers the fasting and postprandial blood glucose levels of patients with type 2 diabetes but is also expected to help patients achieve a weight loss of over 10%. In a key phase III registration trial primarily involving the Asia-Pacific region, with 83.4% of the participants from China, tirzepatide significantly reduced levels of glycated hemoglobin (HbA1c) and, in the 5mg and 10mg dosage groups, participants' average weight decreased by 7.8 kilograms and 10.3 kilograms respectively.
In the field of new energy, the trends of the solar energy market in Germany indicate that as the installed capacity of solar energy increases, adjustments appear in the electricity market. According to SEB Research, by the end of 2023, the total installed capacity of solar energy in Germany has reached 81.7 gigawatts, far exceeding the national average electricity demand load of 52.2 gigawatts. As the season warms, situations where solar power generation capacity exceeds demand start to emerge. In recent weeks, the selling price of solar energy in Germany has dropped by 87%; specifically, from May 11th to May 21st, the weighted average selling price of solar electricity was only 9.1 euros per megawatt-hour (approximately 0.072 RMB/kWh), in contrast, the selling price of electricity in non-solar periods was 70.6 euros per megawatt-hour (approximately 0.555 RMB/kWh). During the peak solar power generation at noon, negative electricity prices even occurred in the German power grid. The development of new energy technologies is bringing changes to the price structure of the power market, and negative electricity prices are no longer uncommon. The "Shanghai Securities News" had reported that as early as December 2019, the Shandong power spot market recorded the country's first negative electricity price event. From May 1st to 2nd, 2023, real-time negative electricity price data in Shandong's power market spot trading center continued for 21 consecutive hours, breaking the record for the duration of negative prices. In July of that year, negative prices were also experienced in Germany, the Netherlands, France, and other EU countries. Nevertheless, as the electricity fees for ordinary consumers are usually pre-negotiated with the power grid company, ordinary consumers generally do not benefit from negative electricity prices.
In the field of aerospace, SpaceX's Starship program is making steady progress. According to reports, SpaceX's Starship is expected to conduct its fourth test flight as early as June 5th. The development and testing of Starship are important steps in humanity's exploration of deep space. The company continuously optimizes its design and performance through repeated high-difficulty test flights, aiming to meet the requirements for future manned deep space missions.
SpaceX is about to conduct the fourth test flight of its Starship spacecraft, a crucial flight test that is awaiting approval from regulatory agencies and could potentially start as early as June 5th. This test flight will focus on testing the rocket's recovery and reusability, especially the soft landing capabilities of the heavy-lift booster on the lower stage. During the landing process, these boosters plan to ignite over the Gulf of Mexico to achieve a soft splashdown at sea, while the upper stage Starship aims to re-enter the atmosphere with controlled posture and ultimately fall into the Indian Ocean.
Looking back at Starship's third test flight on March 14, 2024, that test flight succeeded in entering space and completing technological verification of fuel transfer and payload bay door operations while in orbit. In that mission, the heavy-lift booster attempted to achieve a soft splashdown by igniting to decelerate, but failed to meet the expected goal due to insufficient thrust. As Starship re-entered the atmosphere, it could not effectively use the protection of its heat shield tiles due to attitude control problems, leaving it vulnerable to high-temperature impacts.
Based on the valuable data and feedback from the third test flight, the SpaceX team made a series of improvements. These improvements included the removal of unnecessary thermal separation rings on the super-heavy boosters to reduce their overall mass; moreover, to increase control over the Starship spacecraft's attitude, the team added additional thrusters to the spacecraft to help control its roll.
Comments 0